BRAF and colorectal cancer: Moreover, cmFOLFOXIRI in combination with anti-EGFR monoclonal antibody (cetuximab) is recommended as the first-choice conversion therapy for left-sided colorectal cancer patients with wild-type RAS/BRAF.